LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

Home・Akcijų sąrašas・Illumina Inc

Illumina Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

145.13 0.41

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

141.69

Max

146.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-200M 134M
Pardavimai	-68M 1.1B
P/E Sektoriaus vid.	25.729 49.701
Pelnas, tenkantis vienai akcijai	1.15
Pelno marža	12.282
Darbuotojai	8,600
EBITDA	-144M 301M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-2.07% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.9B 21B
Ankstesnė atidarymo kaina	144.72
Ankstesnė uždarymo kaina	145.13

Naujienos nuotaikos

By Acuity

16%

84%

21 / 345 reitingas Healthcare

Illumina Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-25 08:24; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026-05-25 21:22; UTC

Uždarbis

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026-05-25 20:50; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:20; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:01; UTC

Rinkos pokalbiai

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026-05-25 14:43; UTC

Rinkos pokalbiai

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026-05-25 14:15; UTC

Rinkos pokalbiai

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026-05-25 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-25 12:58; UTC

Rinkos pokalbiai

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026-05-25 12:56; UTC

Rinkos pokalbiai

Uždarbis

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-25 12:34; UTC

Rinkos pokalbiai

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026-05-25 12:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero's Assets Look Strategic -- Market Talk

2026-05-25 11:00; UTC

Rinkos pokalbiai

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026-05-25 10:19; UTC

Rinkos pokalbiai

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026-05-25 10:05; UTC

Uždarbis

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026-05-25 10:04; UTC

Uždarbis

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026-05-25 10:03; UTC

Uždarbis

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026-05-25 10:02; UTC

Uždarbis

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026-05-25 10:01; UTC

Uždarbis

Tenaga Nasional 1Q Net Up 3.7% on Year

2026-05-25 10:00; UTC

Uždarbis

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q EPS MYR0.1883

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Rev MYR17.1B

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Net MYR1.1B

2026-05-25 09:38; UTC

Rinkos pokalbiai

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026-05-25 08:55; UTC

Rinkos pokalbiai

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Akcijų palyginimas

Kainos pokytis

Illumina Inc Prognozė

Kainos tikslas

By TipRanks

-2.07% į apačią

12 mėnesių prognozė

Vidutinis 141.42 USD -2.07%

Aukščiausias 170 USD

Žemiausias 95 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Illumina Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Illumina Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

21 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.